Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
ACS Chemical Biology|November 30, 2018
Structural Basis of Polyketide Synthase O-MethylationMeredith A Skiba, Marissa M Bivins, John R Schultz, et al.Journal of Medicinal Chemistry|November 27, 2023
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2)Young Chen, Brandon Whitefield, Erin Nevius, et al.Nature Biotechnology|June 13, 2017
Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding siteEva-Maria Strauch, Steffen M Bernard, David La, et al.Nature|September 28, 2017
Massively parallel de novo protein design for targeted therapeuticsAaron Chevalier, Daniel-Adriano Silva, Gabriel J Rocklin, et al.Journal of Medicinal Chemistry|September 18, 2025
Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High CancersShota Kikuchi, Jason C Green, Don C Rogness, et al.Science (New York, N.Y.)|November 2, 2019
A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responsesJon M Steichen, Ying-Cing Lin, Colin Havenar-Daughton, et al.Science (New York, N.Y.)|November 3, 2018
Universal protection against influenza infection by a multidomain antibody to influenza hemagglutininNick S Laursen, Robert H E Friesen, Xueyong Zhu, et al.Nature|April 24, 2024
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicaseKristen A Baltgalvis, Kelsey N Lamb, Kent T Symons, et al.Biorxiv : the Preprint Server for Biology|January 7, 2025
Covalent inhibitors of the RAS binding domain of PI3Kα impair tumor growth driven by RAS and HER2Joseph E Klebba, Nilotpal Roy, Steffen M Bernard, et al.Science (New York, N.Y.)|October 9, 2025
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2Joseph E Klebba, Nilotpal Roy, Steffen M Bernard, et al.Pageof 3